We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| -52.00 | -0.50% | 10,408.00 | 803,046 | 16:35:24 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 10,398.00 | 10,402.00 | 10,482.00 | 10,360.00 | 10,450.00 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | USD 45.81B | USD 5.96B | USD 3.8411 | 27.08 | 162.16B |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 16:52:36 | O | 35,093 | 10,408.00 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 24/12/2024 | 08:20 | ALNC |  AstraZeneca and Daiichi withdraw EU application for lung cancer drug |
| 24/12/2024 | 07:00 | UK RNS | AstraZeneca PLC Dato-DXd NSQ NSCLC application withdrawn in EU |
| 23/12/2024 | 10:13 | ALNC | AstraZeneca receives EU approval for Tagrisso lung cancer treatment |
| 23/12/2024 | 07:00 | UK RNS | AstraZeneca PLC Tagrisso approved in EU based on LAURA trial |
| 18/12/2024 | 12:44 | ALNC | PRESS: AstraZeneca sees sales slump in China after arrest of exec - FT |
| 16/12/2024 | 07:00 | UK RNS | AstraZeneca PLC Directorate Change |
| 11/12/2024 | 19:40 | ALNC | IN BRIEF: Merck and AstraZeneca unveil long-term Lynparza results |
| 09/12/2024 | 09:09 | ALNC | AstraZeneca, Daiichi Sankyo hail US breakthrough therapy designation |
| 05/12/2024 | 09:46 | ALNC | AstraZeneca touts US FDA approval for small cell lung cancer treatment |
| 05/12/2024 | 07:00 | UK RNS | AstraZeneca PLC Imfinzi approved in US for limited-stage SCLC |
Astrazeneca (AZN) Share Charts1 Year Astrazeneca Chart |
|
1 Month Astrazeneca Chart |
Intraday Astrazeneca Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 23/12/2024 | 11:35 | AstraZeneca | 6,231 |
| 25/4/2024 | 07:41 | Alzheimer's can be caught .... It's a transmissible disease | 126 |
| 02/11/2021 | 14:29 | ASTRAZENECA, MSD PROSTATE CANCER DRUG GETS CHINA GREEN LIGHT | 2 |
| 20/9/2021 | 14:45 | INDIA'S COVID DEATH RATE IS 278 PER 1 MILLION..UK'S IS 1876..THINK ABOUT IT | 1 |
| 15/9/2021 | 11:17 | Eu | 2 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 2024-12-30 16:52:36 | 10,408.00 | 35,093 | 3,652,479.44 | O |
| 2024-12-30 16:52:36 | 10,408.00 | 226 | 23,522.08 | O |
| 2024-12-30 16:52:36 | 10,408.00 | 116 | 12,073.28 | O |
| 2024-12-30 16:52:36 | 10,408.00 | 155 | 16,132.40 | O |
| 2024-12-30 16:52:36 | 10,408.00 | 134 | 13,946.72 | O |
| Top Posts |
|---|
Posted at 30/12/2024 08:20 by Astrazeneca Daily Update Astrazeneca Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker AZN. The last closing price for Astrazeneca was 10,460p.Astrazeneca currently has 1,550,317,189 shares in issue. The market capitalisation of Astrazeneca is £161,263,994,000. Astrazeneca has a price to earnings ratio (PE ratio) of 27.08. This morning AZN shares opened at 10,450p |
Posted at 04/12/2024 15:00 by fuji99 That's the only news out there on AZN."AstraZeneca (AZN.L)slipped 2.7% to the bottom of the blue-chip index after HSBC analysts cut the target price on the drugmaker's stock to 13,720p from 14,070p." |
Posted at 28/11/2024 09:10 by wskill benralizumab first new treatment for Asthma and COPD for 50 years and injection every 4 to 8 weeks looks like a game changer to me .AZN share price is sure to fall today Edit . benralizumab/Fasenra looks to have been in phase 3 trials since 2013 why would it take so long ,or has there been some improvements made in benralizumab /Fasenra . cost seems a little high $5197 per ml It was approved by US and EU regulators in 2017 but just 7 years later they find that its by injection that it can stop severe asthma and COPD attacks 4 times better than the standard steroid treatment.Better late than never I would say. |
Posted at 25/11/2024 10:51 by wskill The UK stock market never fails to amaze me down 4p on this news,Hope top management actually start to think about this nonsense and move the listing to the US it must be blatantly obvious to them that the UK is not the place for AZN .If this was a US listed company do you think that the share price would react in this manner. Prostate cancer is the second most prevalent cancer in men and the fifth leading cause of male cancer death globally.1 |
Posted at 22/11/2024 16:36 by jam62 JP Morgan Cazenove out with strong buy this morning with £140 share price forecast. |
Posted at 14/11/2024 09:30 by wskill Look at BRBY this morning in comparison to AZN no wonder the UK market is uninvestable AZM beat expectations and upgraded the share price fell on result day.Then we have BRBY a large loss today sales falling also huge lease obligations on shops in prime shopping areas and its romping ahead. |
Posted at 14/11/2024 08:19 by m_night10 #POLX Polarean Imaging 1.6p about to break out above 2p soon. Mcap only $20mil. I see it as a steal for the FDA approved Xenon MRI. No company debt, masssive growth potential in the worlds biggest health market the United States where it's already in 21 clinical settings, best in class next generation MRI. Revenues rising up 3000% to $3mil for 2024 and doubling again next to $6mil in 2025. 1.6p and gap to fill to 3.2p, so 100% rise just to fill the technical gap. ATH 100p. My target is recovery to 25p.Cash runway to minimum of Q2 2026, looks set to be extended given revenues ahead of expectations. Putting this UK recovery play potential on radars. 1. September 18th 2024: Interventional radiology vendor Merit Medical to acquire device portfolio for $210M. APPROX 13P SHARE PRICE EQUIVALENT FOR POLX 2. September 25th 2024: Private equity firm acquiring diagnostic imaging provider for $658M APPROX 48P SHARE PRICE EQUIVALENT FOR POLX 3. October 14th 2024: Hologic to Acquire Gynesonics The women’s health company will be purchased for approximately $350 million. APPROX 22P SHARE PRICE EQUIVALENT FOR POLX 4. Bracco current major TR1 Holder of Polarean splashed out $450MILLION for a diagnostic buyout POLX easy buyout target imv and big riser. DYOR, not advice. |
Posted at 12/11/2024 10:16 by fuji99 Agree Monty that China is the big hurdle for any positive share price movement regardless of the results and progress they make.The market hates uncertainty and these are questions that anyone can ask: What are the repercussions from China ? Is AZN going to be involved in Chinese courts ? Possible big fine if breaches are serious ? Any financial repercussion may hurt AZN numbers thus why the share price is "floating" at the moment. All these uncertainties will continue to weigh on the share price untill all is clarified once for all. |
Posted at 10/11/2024 00:10 by philanderer AstraZeneca has explaining to do after £50 billion value wipe outAt the start of September when its share price was at an all-time high and it was comfortably the UK’s largest company, AstraZeneca PLC (LSE:AZN) management might have been expecting a routine third-quarter update. Two months on however and £50 billion has been wiped from its value with growing questions over its pipeline and operation in China. Poor trial results and some questionable PR – putting out a three- sentence response to the China issue during the middle of Rachel Reeves’ Budget speech for example - have added to the unease. The trial disappointments surround its dato-DXd cancer drug and its fledgling move into the weight loss drug arena. In China, AstraZeneca has confirmed its president there Leon Wang is co-operating with the authorities as part of an ongoing investigation but has given no details, saying it will not comment on speculative media reports. Some City commentators have suggested that the pharma is not directly involved and the share price fall is exaggerated. ShoreCap, in a detailed look at the issue, added Astra could help alleviate investor concerns by providing clarity on its China business and reaffirming its growth prospects in the third quarter update. Whether it chooses to remains to be seen proactiveinvestors.c |
Posted at 05/11/2024 17:24 by philanderer Looking like China relatedRNS from the Company just out 05 November 2024 AZN share price movement As a matter of policy, we do not comment on speculative media reports including those related to ongoing investigations in China. If requested, we will fully cooperate with the Chinese authorities. We continue to deliver our life changing medicines to patients in China and our operations are ongoing. |
Posted at 08/4/2024 13:47 by wad collector Really?Found 22 results: Blackhorse23 - 08 Apr 2024 - 11:28:43 - 6011 of 6012 AstraZeneca - AZN Money moved to APH Blackhorse23 - 05 Apr 2024 - 09:16:44 - 6009 of 6012 AstraZeneca - AZN Blackhorse23 - 21 Mar 2024 - 08:47:26 - 6002 of 6012 AstraZeneca - AZN Money moving to APH [LSE] , excellent profitable healthcare company Blackhorse23 - 21 Feb 2024 - 14:26:56 - 5995 of 6012 AstraZeneca - AZN Money moving to APH , excellent growth health care company Blackhorse23 - 12 Feb 2024 - 11:37:36 - 5981 of 6012 AstraZeneca - AZN Money moving to APH Blackhorse23 - 29 Jan 2024 - 15:32:08 - 5957 of 6012 AstraZeneca - AZN Blackhorse23 - 19 Jan 2024 - 11:52:35 - 5956 of 6012 AstraZeneca - AZN Ha ha hxxps://www.alliance Blackhorse23 - 18 Jan 2024 - 14:23:42 - 5954 of 6012 AstraZeneca - AZN Bought some APH today Blackhorse23 - 09 Jan 2024 - 11:01:43 - 5948 of 6012 AstraZeneca - AZN are they buying APH ?? |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
